AU2019268215A1 - Process for preparing intermediate of antibody drug conjugate - Google Patents

Process for preparing intermediate of antibody drug conjugate Download PDF

Info

Publication number
AU2019268215A1
AU2019268215A1 AU2019268215A AU2019268215A AU2019268215A1 AU 2019268215 A1 AU2019268215 A1 AU 2019268215A1 AU 2019268215 A AU2019268215 A AU 2019268215A AU 2019268215 A AU2019268215 A AU 2019268215A AU 2019268215 A1 AU2019268215 A1 AU 2019268215A1
Authority
AU
Australia
Prior art keywords
reaction
pab
maa
cit
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2019268215A
Other versions
AU2019268215B2 (en
Inventor
Jianmin Fang
Changjiang Huang
Haohua JIE
Xuejing YAO
Hui Ye
Shizhong ZHAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remegen Co Ltd
Original Assignee
Remegen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remegen Co Ltd filed Critical Remegen Co Ltd
Publication of AU2019268215A1 publication Critical patent/AU2019268215A1/en
Application granted granted Critical
Publication of AU2019268215B2 publication Critical patent/AU2019268215B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Description

[0001] The present invention relates to the field of pharmaceutical preparation, specifically to a process for preparing an intermediate of antibody-drug conjugate.
BACKGROUND [0002] Antibody-drug conjugate (abbreviated as ADC) is a class of anti-tumor drugs consisting of three components: antibody, linker and drug. The number of drugs attached to the antibody (Drug-antibody Ratio, DAR) determines the homogeneity of the antibody-drug conjugate. Excessive number of attached drugs will lead to unstable pharmacodynamics, increased drug metabolism, decreased half-life, and increased systemic toxicity.
[0003] The DAR value is primarily determined by the linker. Classical ADCs have two coupling methods: one is amino coupling and the other is thiol coupling, which is currently the most commonly used coupling method. Amino coupling is the coupling of a drug to a lysine (Lys) residue of an antibody via a linker. Since there are 80 lysines on one antibody, 30 of which can be linked, the ADC formed by lysine coupling has a DAR value of 0 to 30, and the product homogeneity is extremely poor. Thiol coupling is to open the interchain disulfide bonds in the antibody first to give free cysteine (Cys) residues, before being coupled to a linker-drug complex capable of pairing with a cysteine residue. Since a single antibody only has 4 pairs of interchain disulfide bonds, 8 free cysteine residues would be generated after the interchain disulfide bonds are all opened. Therefore, the ADCs formed by cysteine residue coupling have DAR values of 0 to 8. Although thiol coupling can better control the number of linkages per antibody, the cleavage of the interchain disulfide bond greatly reduces the stability of the antibody.
[0004] Currently, in addition to the classical amino coupling and thiol coupling, there is a new coupling method: bridging coupling. The bridging coupling method is a new coupling method developed based on thiol coupling, in which the linker is simultaneously coupled to two free thiol groups on the antibody, and the DAR value of the antibody-drug conjugate produced in this manner is 0 to 4. A variety of linkers capable of being covalently linked to an antibody by way of -1 English Translation of PCT/CN2019/087641 bridging coupling are disclosed in a Chinese patent publication CN107921030A, which discloses an intermediate of antibody-drug conjugate (Py-MAA-Val-Cit-PAB-MMAE) (wherein Py is triacryloylhexahydro triazine, its CAS is 959-52-4, and is available from J&K Scientific and Nanjing Chemlin Chemical Industry Co., Ltd.) as shown below on page 42 of the specification.
Figure AU2019268215A1_D0001
Py- MAA-Vai - Ci t- PAB- MMAE [0005] In addition, a process for preparing an intermediate of antibody-drug conjugate (Py-MAA-Val-Cit-PAB-MMAD) in which the Drug is MMAD (Demethyldolastatin) is also disclosed on page 32 of the patent application:
Figure AU2019268215A1_D0002
The process involves first coupling Val-Cit-PAB with Drug (MMAD) to form a Val-Cit-PAB-MMAD conjugate, and then reacting with Py-MAA to form an antibody-drug conjugate intermediate Py-MAA-Val-Cit-PAB-MMAD. Due to high price for the drug (such as MMAD/MMAE or MMAF, etc.) used in the antibody-drug conjugate and great feed loss for the production of drug using the above-mentioned process, the production cost is high, making it not 15 suitable for industrial mass production.
-2English Translation of PCT/CN2019/087641
SUMMARY [0006] The present disclosure provides a process for preparing an intermediate of antibody-drug conjugate, specifically provides a process for preparing an intermediate of antibody-drug conjugate comprising a linker and a drug moiety. The intermediate of antibody-drug conjugate is Py-MAA-Val-Cit-PAB-D, in which Py-MAA-Val-Cit-PAB is the linker, and D represents the attached drug moiety. The process is characterized in that it comprises the following reactions:
Figure AU2019268215A1_D0003
Reaction B
Figure AU2019268215A1_D0004
Drug Moiety D
i) Triazole catalyst i i) Organic Base
Py-MAA-Val-Cit-PAB-PNP
Figure AU2019268215A1_D0005
Py-MAA-Val-CiUPAB-D [0007] Further, the preparation process comprises the following reaction procedure:
Reaction A: dissolving Py-MAA-Val-Cit-PAB-OH in a solvent, adding bis(4-nitrophenyl) carbonate, stirring until dissolved or the solution is slightly turbid, and then adding an organic base;
Reaction B: after completion of Reaction A, adding a triazole catalyst, the drug moiety D, and an organic base, and after completion of the reaction, carrying out purification to obtain Py-MAA-Val-Cit-PAB-D. Preferably, pre-HPLC is used for the purification.
[0008] Further, the drug moiety D is an auristatin class cytotoxic agent, an anthramycin class cytotoxic agent, an anthracycline class cytotoxic agent or a puromycin class cytotoxic agent.
[0009] Preferably, the auristatin class cytotoxic agent is selected from the group consisting of MMAE, MMAF, MMAD and a derivative thereof; the anthramycin class cytotoxic agent is
-3English Translation of PCT/CN2019/087641 anthramycin; the anthracycline class cytotoxic agent is selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin and mitoxantrone; and the puromycin class cytotoxic agent is puromycin .
[0010] Preferably, the Py-MAA-Val-Cit-PAB-D has the structures as represented by Formulas (1-11):
Figure AU2019268215A1_D0006
(1)
Figure AU2019268215A1_D0007
Figure AU2019268215A1_D0008
(3)
Figure AU2019268215A1_D0009
(4)
-4English Translation of PCT/CN2019/087641
Figure AU2019268215A1_D0010
-5English Translation of PCT/CN2019/087641
Figure AU2019268215A1_D0011
(10)
Figure AU2019268215A1_D0012
[0011] Further, the solvent is a polar solvent and/or a non-polar solvent. The polar solvent is one or more selected from the group consisting of DMF, DMA and NMP; the non-polar solvent is 5 one or more selected from the group consisting of dichloromethane and carbon tetrachloride.
[0012] Further, the organic base is one or more selected from the group consisting of Ν,Ν-diisopropylethylamine, triethylamine and pyridine, preferably, one or two selected from the group consisting of Ν,Ν-diisopropylethylamine and pyridine.
[0013] Further, the triazole catalyst is one or more selected from the group consisting of 10 1-hydroxybenzotriazole, 1-hydroxy-7-azabenzo triazole, ethyl
-hydroxy-1H-1,2,3-triazole-4-carboxylate, preferably 1 -hydroxybenzotriazole.
[0014] Further, the reaction temperature of the Reaction A is 5 to 35 °C, and the reaction duration is 2 to 10 hours.
[0015] Preferably, in the Reaction A, controlling the temperature of the reaction system to be in 15 a range from 5 to 15 °C prior to the addition of bis(4-nitrophenyl) carbonate, and further preferably 10 °C.
[0016] Preferably, in the Reaction A, controlling the temperature of the reaction system to be in a range from 20 to 35 °C after the addition of the organic base, preferably 30 °C.
-6English Translation of PCT/CN2019/087641 [0017] Further, the reaction temperature of the Reaction B ranges from 5 to 30 °C, and the reaction duration ranges from 15 to 48 hours.
[0018] Preferably, in the Reaction B, controlling the temperature of the reaction system to be in a range from 5 to 15 °C prior to the addition of the triazole catalyst, preferably 10 °C.
[0019] Preferably, in the Reaction B, controlling the temperature of the reaction system to be in a range from 15 to 30 °C after the addition of the organic base, preferably 20 °C. Further, the molar ratio of Py-MAA-Val-Cit-PAB-OH, bis(4-nitrophenyl) carbonate and the organic base in Reaction A is 1: 1-5: 1-3.
[0020] Further, the molar ratio of the triazole catalyst, MMAE, the organic base and Py-MAA-Val-Cit-PAB-OH in the Reaction B is 1-3: 1-3 : 1.5-30 :1.
[0021] Further, the present disclosure also provides using any one of the above-mentioned preparation processes to prepare an intermediate of an antibody-drug conjugate, which is Py-MAA-Val-Cit-PAB-MMAF, and its structure is as represented by Formula (2):
Figure AU2019268215A1_D0013
[0022] Further, the present disclosure also provides using any one of the above-mentioned preparation processes to prepare an intermediate of antibody-drug conjugate, which is Py-MAA-Val-Cit-PAB-MMAD, and its structure is as represented by Formula (3):
Figure AU2019268215A1_D0014
[0023] Further, the present disclosure also provides using any one of the above-mentioned preparation processes to prepare an intermediate of antibody-drug conjugate, which has a structure as represented by Formula (4):
English Translation of PCT/CN2019/087641
Figure AU2019268215A1_D0015
Figure AU2019268215A1_D0016
(4) [0024] Further, the present disclosure also provides using any one of the above-mentioned preparation processes to prepare an intermediate of antibody-drug conjugate, which has a structure as represented by Formula (5):
Figure AU2019268215A1_D0017
(5) [0025] Further, the present disclosure also provides using any one of the above-mentioned preparation processes to prepare an intermediate of antibody-drug conjugate, which has a structure as represented by Formula (6):
Figure AU2019268215A1_D0018
(6) [0026] Further, the present disclosure also provides using any one of the above-mentioned preparation processes to prepare an intermediate of antibody-drug conjugate, which has a structure as represented by Formula (7):
Figure AU2019268215A1_D0019
-8English Translation of PCT/CN2019/087641 [0027] Further, the present disclosure also provides using any one of the above-mentioned preparation processes to prepare an intermediate of antibody-drug conjugate, which has a structure as represented by Formula (8):
Figure AU2019268215A1_D0020
(8) [0028] Further, the present disclosure also provides using any one of the above-mentioned preparation processes to prepare an intermediate of antibody-drug conjugate, which has a structure as represented by Formula (9):
Figure AU2019268215A1_D0021
(9) [0029] Further, the present disclosure also provides using any one of the above-mentioned preparation processes to prepare an intermediate of antibody-drug conjugate, which has a structure as represented by Formula (10):
Figure AU2019268215A1_D0022
(10) [0030] Further, the present disclosure also provides using any one of the above-mentioned preparation processes to prepare an intermediate of antibody-drug conjugate, which has a 15 structure as represented by Formula (11):
-9English Translation of PCT/CN2019/087641
Figure AU2019268215A1_D0023
[0031] In some particular embodiments, the process comprises the following steps:
Reaction A: dissolving Py-MAA-Val-Cit-PAB in DMF, adding bis(p-nitrophenyl)carbonate, stirring until they are dissolved or slightly turbid before adding N,N-diisopropylethylamine 5 dropwise, separating and purifying to obtain Py-MAA-Val-Cit-PAB-PNP;
Reaction B: dissolving Py-MAA-Val-Cit-PAB-PNP in DMF, adding 1-hydroxybenzotriazole, MMAE, Ν,Ν-diisopropylethylamine and pyridine, carrying out pre-HPLC purification after completion of the reaction to obtain compound Py-MAA-Val-Cit-PAB-MMAE as represented by Formula (1).
wherein the structure of the Py-MAA-Val-Cit-PAB-PNP is shown as follow:
Figure AU2019268215A1_D0024
Py-MAA-Val-CIt-PAB-PNP [0032] Furthermore, the separation and purification in the above-mentioned reaction process may be as follows:
(1) centrifuging the reaction solution of Reaction A to obtain a supernatant;
(2) adding solvent 1 to the supernatant, and stirring well;
(3) adding solvent 2 dropwise at 0 to 10 °C, and stirring well;
(4) filtering under suction to obtain a filter cake;
- 10English Translation of PCT/CN2019/087641 (5) re-dissolving the filter cake in a mixed solution of solvent 3 and solvent 4;
(6) adding the resultant dropwise to solvent 5 at 0 to 10 °C, and stirring;
(7) filtering under suction to obtain an off-white powder, which is purified Py-MAA-Val-Cit-PAB-PNP.
Thereinto, the solvent 1 is a moderately polar solvent, preferably selected from the group consisting of ethyl acetate, dichloromethane, methanol, methyl tert-butyl ether and the like, most preferably ethyl acetate;
the solvent 2 is a weakly polar solvent, preferably selected from the group consisting of petroleum ether, «-hexane, «-pentane, cyclohexane and the like, most preferably petroleum ether;
the solvents 3 and 4 are solvents in which Py-MAA-Val-Cit-PAB-PNP is easy to dissolve, preferably selected from the group consisting of acetic acid, trifluoroacetic acid, formic acid, methanol, ethanol and the like, most preferably acetic acid and methanol;
the solvent 5 is a solvent in which Py-MAA-Val-Cit-PAB-PNP is poorly soluble, preferably selected from the group consisting of acetonitrile, ethyl acetate, dichloromethane, water and the like, most preferably water.
The volume/weight ratio of the solvent 1, the solvent 2, the solvent 3 and the solvent 4 and Py-MAA-Val-Cit-PAB is 40-100: 80-200: 5-15: 1-3: 15-30: 1 .
[0033] In some particular embodiments, the above-mentioned separation and purification may be as follows:
(1) centrifuging the intermediate product A to obtain a supernatant;
(2) adding ethyl acetate to the supernatant, and stirring well;
(3) adding petroleum ether dropwise at 0 to 10 °C, and stirring well;
(4) filtering under suction, and taking the filter cake;
(5) re-dissolving the filter cake in a mixed solution of acetic acid and methanol;
(6) adding purified water dropwise at 0 to 10 °C, and stirring;
(7) filtering under suction to obtain a off-white powder, which is purified
-11 English Translation of PCT/CN2019/087641
Py-MAA-Val-Cit-PAB-PNP.
[0034] Compared with the process for preparing an intermediate of the antibody-drug conjugate (Py-MAA-Val-Cit-PAB-MMAD) disclosed by the Chinese patent publication CN107921030A on page 43 of the specification, the process for preparing an intermediate of the 5 antibody-drug conjugate provided by the present disclosure significantly reduces the feed loss for drug moiety (such as MMAD/MMAE or MMAF, etc.) as drug moiety is involved in the last step of the reaction, thereby effectively reducing production costs, as well as increasing production efficiency. In addition, the process provided by the present disclosure is simple, environmentally friendly and suitable for large-scale industrialization.
DETAILED DESCRIPTION [0035] Abbreviations
Abbreviations Structure / English name
Py A O O Triacryloylhexahydro triazine
Py-MAA II 0 JL γ Y OH O O Triacryloylhexahydro triazine-mercaptoacetic acid
- 12 English Translation of PCT/CN2019/087641
Py-MAA-Val-Cit-PAB-OH 0<γΑ. A s Y h J AA0H J S H J ςH Ί NH cYnh2 Triacryloylhexahydro triazine-mercaptoacetic acid-valine-citrulline-p-aminobenzyl alcohol
Py-MAA-Val-Cit-PAB-PNP A ϋ Y Η n II II h II = h 0 0 Ox ^NH O^NH2 Triacryloylhexahydro triazine-mercaptoacetic acid-valine-citrulline-p-aminobenzyloxycarbonyl-p-nitrophenyl ester
Py-MAA-Val-Cit-PAB-MMAE Y ο γ H o jaAAYAAAyAi γγΝ ί zaAnAAA 2 ..-J cA ο-., o 1 U 1 S H 8 y 'NH o;!‘-nh.. Triacryloylhexahydro triazine-mercaptoacetic acid-valine-citrulline-p-aminobenzyloxycarbonyl Monomethyl auristatin E
MMAE Y H 9 Y' A/ J H 9H 1 0 Ax 1 °x 0 °x 0
- 13 English Translation of PCT/CN2019/087641
MMAD ^N 1 N ,,,ί 0 O„. H °
o 'X'N*' I
MMAF Γ N 0 H
^N Ύ Ν'' fl f II Ί
1 0 X 1 0,. 0 0,^ 0 O OH -
NPC o2n. n
TJ oAAJ-
Bis(4-nitrophenyl) carbonate
Anthramycin OH H Λ, N- OH
N.J.,. _,nh2
0 0
Daunorubicin 0 OH \^o
Γ T T 7-oh
0.. 0 OH 0, v-\.AH2
°V’0H
Doxorubicin 0 N ΙΪ OH Ά /P
II N ^OH
o OH 0 ^-'X^NHa
°'Ά'0Η
- 14English Translation of PCT/CN2019/087641
Epirubicin 0 OH OH OH
¥ o.. r o OH T< 0 ^NH2
O^J ^0 H
Idarubicin 0 OH yo
^s7»OH
0 OH Ϊ*Η ,,νη.
0^- '*ΌΗ
Valrubicin 0=\ o- -HO OH 0
Ό || ί J
r>r/ .0 ...O OH 0
HO HN 0
Mitoxantrone OH \ |f 0 HN'' H όη
OH 0 HN._ H ,.0 Η
- 15 English Translation of PCT/CN2019/087641 puromycin
Figure AU2019268215A1_D0025
[0036] Definitions [0037] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as interpreted by a person having ordinary skill in the art.
[0038] Although numerical ranges and parameter approximations are shown in a broad scope in the present disclosure, the numerical values shown in specific embodiments are described as being as accurate as possible. However, any numerical value inherently contains certain errors due to the standard deviations present in their respective measurements. In addition, all ranges disclosed herein are to be interpreted as encompassing any and all sub-ranges. For example, the stated range of “1 to 10” should be considered to contain any and all subranges between the minimum 1 and the maximum 10 (including the endpoints); that is all subranges starting with a minimum of 1 or greater, such as 1 to 6.1, and subranges ending with a maximum of 10 or less, such as 5.5 to 10. In addition, any reference that is referred to as “incorporated herein” is interpreted to be incorporated in its entirety.
[0039] In addition, it should be noted that, as used in the specification, the singular forms include the plural forms of the subject matter, unless clearly and explicitly limited to one subject matter. The term “or” can be used interchangeably with the term “and/or” unless the context clearly dictates otherwise.
[0040] The term “antibody-drug conjugate” as used in the present disclosure represents a compound in which an antibody/antibody functional fragment, a linker, and a drug moiety are chemically linked together, and the structure thereof usually consists of three parts: an antibody or antibody ligand, a drug moiety, and a linker that couples the antibody or antibody ligand and
- 16English Translation of PCT/CN2019/087641 the drug. Currently the preparation of antibody-drug conjugates is usually divided into two steps: the first step is to chemically react a linker with a drug moiety to form a “linker-drug” conjugate, and the second step is to covalently couple the linker part of the “linker-drug” conjugate to an antibody/antibody functional fragment via a thiol or amino group. The term “intermediate of antibody-drug conjugate” as used in the present disclosure refers to the “linker-drug” conjugate as described above, and further, the “intermediate of antibody-drug conjugate” referred to in the present disclosure generally refers to those “linker-drug” conjugate in which a linker and a drug are coupled together by a -CO-NH- bond via amine transesterification.
[0041] The terms “linker” and “linker part” as used in the present disclosure refers to the part of an antibody-drug conjugate that links an antibody to a drug, which may be cleavable or non-cleavable. A cleavable linker (i.e., a linker which is cleavable or a biodegradable linker) can be cleaved inside or on the target cell so as to release the drug. In some embodiments, the linker of the present disclosure is selected from cleavable linkers, such as a disulfide-based linker (which is selectively cleaved in tumor cells which have higher concentration of sulfhydryl groups), a peptide linker (which is cleaved by an enzyme in tumor cells), or a hydrazone linker. In another embodiments, the linker of the present disclosure is selected from non-cleavable linkers (i.e. a linker which is not cleavable), such as a thioether linker. In another embodiments, the linker of the present disclosure is a combination of a cleavable linker and a non-cleavable linker.
[0042] The terms “drug” and “drug moiety” as used in the present disclosure generally refers to any compound having desired biological activity and reactive functional group for the preparation of the conjugates of the present disclosure. The desired biological activity includes diagnosing, curing, alleviating, treating, preventing diseases in humans or other animals. As novel drugs are continuously discovered and developed, these novel drugs should also be included in the drugs of the present disclosure. Specifically, the drug includes, but is not limited to, cytotoxic drugs, cell differentiation factors, stem cell trophic factors, steroid drugs, drugs for treating autoimmune diseases, anti-inflammatory drugs, or drugs for infectious diseases. More specifically, the drug includes, but is not limited to, tubulin inhibitors or DNA, RNA damaging agents.
[0043] Examples
- 17English Translation of PCT/CN2019/087641 [0044] The followings are examples of the methods and compositions of the present disclosure. It should be understood that various other embodiments may be implemented in light of the above definitions and the general description.
[0045] Example 1 Preparation of Py-MAA
Figure AU2019268215A1_D0026
$ Py Py-IIAA [0046] Compound Py (1.87 g, 7.51 mmol) (CAS: 959-52-4) and EtsN (104 pL, 0.75 mmol) were dissolved in anhydrous CH2CI2 (40 mL), a solution of thioglycolic acid (103.9 pL, 1.50 mmol) in CH2CI2 (40 mL) was added dropwise. After completion of the addition, the temperature of the system was raised to room temperature and it was stirred overnight. After completion of 10 the reaction, the solvent was removed in vacuo, and the crude product was purified by column chromatography to obtain white solid Py-MAA (1.87 g, 40.1%).
[0047] Example 2 Comparative Example: Preparation of Py-MAA-Val-Cit-PAB-MMAE (which is the process disclosed on page 32 of the specification of the Chinese patent publication CN107921030A).
[0048] The procedure and method are shown as below:
Figure AU2019268215A1_D0027
Fmoc-Val-Cit-PAB-PNP
Figure AU2019268215A1_D0028
- 18English Translation of PCT/CN2019/087641
Figure AU2019268215A1_D0029
Figure AU2019268215A1_D0030
T Val-Cit-PAB-MMAE
C NII,
Figure AU2019268215A1_D0031
'NH
Py-MAA-Val-Cit-PAB-MMAE [0049] (1) Preparation of Fmoc-Val-Cit-PAB-MMAE [0050] Fmoc-Val-Cit-PAB-PNP (388.4 mg, 0.507 mmol) was taken and dissolved in DMF (40 m) under the protection of nitrogen at 0 °C, and HOBt (68.4 mg, 0.507 mmol) and compound MMAE (400.0 mg, 0.558 mmol) were added. After 15 minutes, pyridine (8 ml) and DIPEA (106.2 pL, 0.608 mmol) were added and reacted at 0 °C for 30 minutes. The temperature was increased to room temperature and it was stirred for 3 hours. The reaction mixture was supplemented with DIPEA (106.2 pL, 0.608 mmol) and the reaction was continued at room temperature for 24 hours. After completion of the reaction, the mixture was concentrated in vacuo. The crude product was purified by column chromatography to obtain a white solid compound Fmoc-Val-Cit-PAB-MMAE (325 mg, yield 47.7%).
[0051] (2) Preparation of Val-Cit-PAB-MMAE [0052] Compound Fmoc-Val-Cit-PAB-MMAE (325 mg, 0.289 mmol) was dissolved in DMF (6 mL), before diethylamine (3 mL) was added, and the reaction was continued with stirring for 2.5 hour. After completion of the reaction, the solvent was removed under reduced pressure to obtain a crude product Val-Cit-PAB-MMAE (220 mg, yield: 67.8%), which can be used for the next reaction directly without purification.
[0053] 3) Synthesis of Py-MAA-Val-Cit-PAB-MMAE [0054] Compound Py-MAA (80.2 mg, 0.235 mmol), HOBt (31.8 mg, 0.235 mmol) and DIC (29.6 mg, 0.235 mmol) were taken and dissolved in DMF (10 mL) and cooled to 0 °C in an ice bath. Compound Val-Cit-PAB-MMAE (220.0 mg, 0.196 mmol) and DIPEA (25.3 mg, 0.196
- 19English Translation of PCT/CN2019/087641 mmol) were added to the reaction solution, the temperature was raised to room temperature and the reaction was performed for 24 hours. After completion of the reaction, the crude product was purified by column chromatography (methanol: dichloromethane = 60:1- 30:1) to obtain a white solid compound Py-MAA-Val-Cit-PAB-MMAE (147.4 mg, yield 52%). LCMS m/z(ES+), 1445 .78 (M+H)+.
[0055] Py-MAA-Val-Cit-PAB-MMAE was prepared by the process for preparing Py-MAA-Val-Cit-PAB-MMAD as disclosed on page 32 of the specification of Chinese patent publication CN107921030A. The feed amount of MMAE was 400 mg, and the obtained Py-MAA-Val-Cit-PAB-MMAE was 147.4 mg.
[0056] Example 3 Improved Preparation Method of Py-MAA-Val-Cit-PAB-MMAE [0057] (1) Preparation of Py-MAA-Val-Cit-PAB
Figure AU2019268215A1_D0032
Py-MAA VnKW-PAlMMI Py-MAA-Val-Cit-PAB-OH [0058] Compound Py-MAA (10.00 g, 29.33 mmol) was put in tetrahydrofuran (200 mL), before Ν,Ν'-Carbonyldiimidazole (7.13 g, 44.00 mmol) and Val-Cit-PAB-OH (13.34 g, 35.20 mmol) were added, and stirred at room temperature for 24 hours. Petroleum ether (200 mL) was added, stirred for 0.5 hours, and filtered to obtain a white solid. The white solid was purified by preparative high performance liquid chromatography, the resultant was subjected to rotary evaporation to obtain Py-MAA-Val-Cit-PAB-OH (6.67 g, 32.4%, a white solid powder).
[0059] (2) Preparation of Py-MAA-Val-Cit-PAB-PNP
Figure AU2019268215A1_D0033
Py-MAA-Val-CH-FAB Py-MAA-Val-CiE-PAB-PhiP [0060] Py-MAA-Val-Cit-PAB-OH (10.00 g, 1.0 eq) and DMF (VDMF/WPy.MAA-vai-cit-PAB = 15-25 mL/g) were added into a three neck flask under the protection of nitrogen, stirred under the
-20English Translation of PCT/CN2019/087641 protection of nitrogen until the solid was dissolved or the solution was slightly turbid. The temperature was reduced to 10 °C for the three neck flask, NPC (1.5-2.5 eq, 6.50-10.83 g) solid was added in one portion and stirred until dissolved or until the solution was slightly turbid. DIPEA (1.0-1.5 eq, 1.84-2.76 g) was added dropwise under the protection of nitrogen. The temperature was raised to 30 °C, and the reaction was monitored by UPLC until the purity of Py-MAA-Val-Cit-PAB was less than 5.0%, then the reaction was terminated.
[0061] The reaction solution was centrifuged, and the supernatant was poured into a beaker of suitable size, into which EA (VEA/Wpy_MAA-vai-cit-PAB = 60 ± 2) was added and stirred with an electric mixer; PE (VpE/Wpy_MAA-vai-cit-PAB = 120 ± 2) was added dropwise at 0 to 6 °C, and stirred for 20 to 30 minutes after drop wise addition. After suction filtration, the filter cake was taken, and dissolved with acetic acid (VACoH/Wpy.MAA-vai-cit-PAB=7) and methanol (VMeOH/Wpy-MAA-vai-cit-PAB) to obtain a solution.
[0062] Purified water (Vwater/Wpy-MAA-vai-cit-PAB = 21) was poured into a beaker of suitable size, mechanically stirred, and cooled to about 3 °C. The above-mentioned solution was added dropwise to purified water and stirred for 15 minutes after the dropwise addition. After suction filtration, the filter cake was obtained and lyophilized to give Py-MAA-Val-Cit-PAB-PNP (a white to off-white powder, 10.69 g, yield 86.54%).
[0063] (3) Preparation of Py-MAA-Val-Cit-PAB-MMAE
Figure AU2019268215A1_D0034
Figure AU2019268215A1_D0035
Ο· '·Η2
Py-MAA-Val-Cii-PAB-MMAE [0064] Py-MAA-Val-Cit-PAB-PNP (9.00 g, 1.0 eq) and DMF (VDMF/Wpy_MAA-vai-cit-PAB-PNP —
-21 English Translation of PCT/CN2019/087641
15.0-25.0 mL/g) were added into a reaction vessel, stirred under the protection of nitrogen until clear or slightly turbid. The internal temperature was maintained at 10 °C, while HOBt (2.10 g, 1.5 eq) was added and stirred for 20 minutes. MMAE (8.93 g, 1.2 eq) was added, and the stirring was continued for 20 minutes. A mixed solution of DIPEA (1.34 g, 1.0 eq) and pyridine (Vpyridine/VoiPEA = 5) was added dropwise, and the temperature was raised to maintain the internal temperature at 20 °C. After 36 hours of reaction, UPLC monitoring was performed once every other hour, and when the purity of MMAE in the reaction solution was < 2.00%, the reaction was terminated.
[0065] A suitable sized beaker was taken, into which a saturated aqueous sodium chloride solution (referred to as brine, Vbrine/Vreaction solution = 10) was added, and the temperature was reduced until the internal temperature was 5 °C. The reaction solution was added dropwise to saturated sodium chloride solution. A crude product was obtained by centrifugation, and purified using preparative high performance liquid chromatography. After lyophilization, Py-MAA-Val-Cit-PAB-MMAE (a white powder, 9.79 g, yield 65.27%) was obtained.
[0066] In the present example, the feed amount of MMAE was 8.93 g, with the obtained amount of Py-MAA-Val-Cit-PAB-MMAE being 9.79 g.
[0067] Comparing the processes provided in Example 2 and Example 3 in terms of the feed amount of MMAE and the mass of the final product (the comparison results are shown in Table 1), it can be seen from Table 1 that the final obtained amount of Py-MAA-Val-Cit-PAB-MMAE prepared by the preparation process of Example 2 was 147.4 mg while the feed amount of MMAE was 400 mg; the final obtained amount of Py-MAA-Val-Cit-PAB-MMAE prepared by the preparation process of Example 3 was 9.79 g while the feed amount of MMAE was 8.93 g.
Table 1 Comparison of Feed Amount of MMAE and Obtained Amount of Final Product
Examples Feed Amount of MMAE Final Obtained Amount of Py-MAA-Val-C it-PAB-MMAE Input-output Ratio of MMAE (Feed Amount of MMA/ Final Obtained Amount of Py-MAA-Val-Cit-PAB-MMAE Percentage Reduction in Feed Amount compared with Comparative Example (Example 2)
Example 2 400 mg 147.4 mg 2.71 -
Example 3 8.93 g 9.79 g 0.91 66.4%
[0068] The input-output rate of MMAE represents how many units of MMAE are required to
-22 English Translation of PCT/CN2019/087641 be fed in order to obtain each unit mass of Py-MAA-Val-Cit-PAB-MMAE. As can be seen from Table 1, by using the method of Example 2, 2.71 unit mass of MMAE is required to obtain 1 unit mass of Py-MAA-Val-Cit-PAB-MMAE; while by adopting the method of Example 3, only 0.91 unit mass of MMAE is required to be fed. The feed amount reduced by 66.4%, which significantly reduces production costs.
[0069] The above described is merely a preferred embodiment, which is only illustrative and not limiting the combinations of features necessary to practice the invention. The provided title is not to limit the various embodiments of the invention. Terms such as “comprising” and “including” are not intended to limit. In addition, unless otherwise indicated, plural forms is included when there is no numeral modification, and “or” means “and/or”. Unless otherwise defined herein, the meaning of all technical and scientific terms used herein is the same as what is commonly interpreted by a person having ordinary skill in the art.
[0070] All publications and patents mentioned in this application are hereby incorporated by reference. Numerous modifications and variations of the described methods and compositions of the present invention are obvious to a person having ordinary skill in the art. Although the invention has been described by way of specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to these specific embodiments. In fact, those numerous modifications and variations used to practice the modes of the present invention, which are obvious to a person having ordinary skill in the art, are intended to be included within the scope of the appended claims.

Claims (7)

1. A process for preparing an intermediate of antibody-drug conjugate comprising a linker and a drug moiety, in which the intermediate of antibody-drug conjugate is Py-MAA-Val-Cit-PAB-D, the Py-MAA-Val-Cit-PAB in the intermediate is the linker and the D in the intermediate represents the attached drug moiety, and the attached drug moiety contains free amino group, wherein it comprises the following reactions:
Reaction A
Figure AU2019268215A1_C0001
Py-MAAA/al-CiLPABOH
Figure AU2019268215A1_C0002
Py-MAA’V8^it>PAB’PNP
Reaction B
Figure AU2019268215A1_C0003
Py-M AA-Vai-Cit- PAB-PN P
Drug Moiety D
i) Triazole catalyst i ί) Organic Base
Figure AU2019268215A1_C0004
Py41AA‘VakCit-PAB-D
2. The process according to claim 1, wherein
Reaction A: dissolving Py-MAA-Val-Cit-PAB-OH in a solvent, adding bis(4-nitrophenyl) carbonate, stirring until dissolved or the solution is slightly turbid, and then adding an organic base;
Reaction B: after completion of Reaction A, adding a triazole catalyst, the drug moiety D and an organic base, and after completion of the reaction, carrying out purification to obtain Py-MAA-Val-Cit-PAB-D.
3. The process according to claim 1 or 2, wherein the drug moiety D is an auristatin class cytotoxic agent, an anthramycin class cytotoxic agent, an anthracycline class cytotoxic agent or a puromycin class cytotoxic agent.
-24English Translation of PCT/CN2019/087641
4. The process according to claim 3, wherein the auristatin class cytotoxic agent is selected from the group consisiting of MMAE, MMAF, MMAD and a derivative thereof; the anthramycin class cytotoxic agent is anthramycin or a derivative thereof; the anthracycline class cytotoxic 5 agent is selected from the group consisiting of daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin, mitoxantrone and a derivative thereof; and the puromycin class cytotoxic agent is puromycin or a derivative thereof.
Figure AU2019268215A1_C0005
-25 English Translation of PCT/CN2019/087641
Figure AU2019268215A1_C0006
Figure AU2019268215A1_C0007
(4)
Figure AU2019268215A1_C0008
Figure AU2019268215A1_C0009
(5)
Figure AU2019268215A1_C0010
(6)
Figure AU2019268215A1_C0011
(7) (8)
-26English Translation of PCT/CN2019/087641
Figure AU2019268215A1_C0012
(9) (10)
Figure AU2019268215A1_C0013
6. The process according to any one of the preceding claims, wherein the solvent is a polar
5 solvent and/or a non-polar solvent, the polar solvent is one or more selected from the group consisting of DMF, DMA and NMP; the non-polar solvent is one or more selected from the group consisting of dichloromethane and carbon tetrachloride.
7. The process according to any one of the preceding claims, wherein the organic base is one
10 or more selected from the group consisting of Ν,Ν-diisopropylethylamine, triethylamine and pyridine, preferably one or two selected from the group consisting of Ν,Ν-diisopropylethylamine and pyridine.
8. The process according to any one of the preceding claims, wherein the triazole catalyst is
15 one or more selected from the group consisting of 1-hydroxybenzotriazole,
-27English Translation of PCT/CN2019/087641 l-hydroxy-7-azabenzotriazole and ethyl l-hydroxy-lH-l,2,3-triazole-4-carboxylate, preferably 1 -hydroxybenzotriazole.
9. The process according to any one of the preceding claims, comprising: in the Reaction A, controlling the temperature of the reaction system to be in the range from 5 to 15 °C prior to the addition of bis(4-nitrophenyl) carbonate, preferably 10 °C; and further preferably, in the Reaction A, controlling the temperature of the reaction system to be in the range from 20 to 35 °C after addition of the organic base, preferably 30 °C.
10. The process according to any one of the preceding claims, comprising: in the Reaction B, controlling the temperature of the reaction system to be in the range from 5 to 15 °C prior to the addition of the triazole catalyst, preferably 10 °C; further preferably, in the Reaction B, controlling the temperature of the reaction system to be in the range from 15 to 30 °C after the addition of the organic base, preferably 20 °C.
11. The preparation process according to any one of the preceding claims, wherein, in the Reaction A, the molar ratio of Py-MAA-Val-Cit-PAB-OH. bis(4-nitrophenyl) carbonate and the organic base is 1: 1-5: 1-3.
12. The process according to any one of the preceding claims, wherein, in the Reaction B, the molar ratio of the triazole catalyst, MMAE, the organic base and Py-MAA-Val-Cit-PAB-OH is 1-3: 1-3: 1.5-30: 1.
13. The process according to any one of the preceding claims, comprising: after completion of the Reaction B, carrying out pre-HPLC purification to obtain Py-MAA-Val-Cit-PAB-D.
14. The process according to any one of the preceding claims, wherein purification is carried
-28 English Translation of PCT/CN2019/087641 out in Reaction A by the following method to obtain Py-MAA-Val-Cit-PAB-PNP:
(1) centrifuging the reaction solution of Reaction A to obtain a supernatant;
(2) adding solvent 1 to the supernatant, and stirring well;
(3) adding solvent 2 dropwise at 0 to 10 °C, and stirring well;
(4) filtering under suction to obtain a filter cake;
(5) re-dissolving the filter cake in a mixed solution of solvent 3 and solvent 4;
(6) adding the resultant dropwise to solvent 5 at 0 to 10 °C, and stirring;
(7) filtering under suction to obtain an off-white powder, which is purified Py-MAA-Val-Cit-PAB-PNP;
wherein the solvent 1 is a moderately polar solvent, preferably selected from the group consisting of ethyl acetate, dichloromethane, methanol, methyl tert-butyl ether and the like, most preferably ethyl acetate; the solvent 2 is a weakly polar solvent, preferably selected from the group consisting of petroleum ether, //-hexane, //-pentane, cyclohexane and the like, most preferably petroleum ether; the solvent 3 and solvent 4 are solvents in which Py-MAA-Val-Cit-PAB-PNP is easy to dissolve, preferably selected from the group consisting of acetic acid, trifluoroacetic acid, formic acid, methanol, ethanol and the like, most preferably acetic acid and methanol; the solvent 5 is preferably selected from the group consisting of acetonitrile, ethyl acetate, dichloromethane, water and the like, most preferably water.
15. The process according to any one of the preceding claims, wherein the reactions are carried out under the protection of nitrogen.
AU2019268215A 2018-05-21 2019-05-20 Process for preparing intermediate of antibody drug conjugate Active AU2019268215B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810487856.4 2018-05-21
CN201810487856.4A CN110507824A (en) 2018-05-21 2018-05-21 A kind of Anti-mesothelin antibodies and its antibody drug conjugate
PCT/CN2019/087641 WO2019223653A1 (en) 2018-05-21 2019-05-20 Preparation process of antibody drug conjugate intermediate

Publications (2)

Publication Number Publication Date
AU2019268215A1 true AU2019268215A1 (en) 2019-12-19
AU2019268215B2 AU2019268215B2 (en) 2021-03-18

Family

ID=68616215

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019272250A Active AU2019272250B2 (en) 2018-05-21 2019-05-15 Anti-mesothelin antibody and antibody-drug conjugate thereof
AU2019268215A Active AU2019268215B2 (en) 2018-05-21 2019-05-20 Process for preparing intermediate of antibody drug conjugate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2019272250A Active AU2019272250B2 (en) 2018-05-21 2019-05-15 Anti-mesothelin antibody and antibody-drug conjugate thereof

Country Status (12)

Country Link
US (2) US20220056147A1 (en)
EP (2) EP3695852A4 (en)
JP (3) JP2021523874A (en)
KR (3) KR20200120728A (en)
CN (3) CN110507824A (en)
AU (2) AU2019272250B2 (en)
BR (2) BR112020014380A2 (en)
CA (2) CA3082160C (en)
RU (2) RU2747995C1 (en)
SG (2) SG11202011159QA (en)
TW (1) TWI714092B (en)
WO (2) WO2019223579A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11717575B2 (en) 2019-05-20 2023-08-08 Mabplex International Co., Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
CN111560072B (en) * 2020-07-16 2020-12-11 上海恒润达生生物科技有限公司 Anti-human MSLN antibodies and MSLN-targeted immune effector cells
EP4129335A4 (en) 2020-09-01 2024-04-24 Remegen Co Ltd Anti-c-met antibody-drug conjugate and applications thereof
JP2023169444A (en) * 2020-10-01 2023-11-30 株式会社Epsilon Molecular Engineering Cross-linked peptide capable of binding to target protein, method for producing crosslinked peptide, and pharmaceutical composition containing crosslinked peptide as active ingredient
KR20230165255A (en) * 2021-03-31 2023-12-05 레메젠 코, 리미티드 Methods for preparing and purifying antibody drug conjugate intermediates
WO2022237666A1 (en) 2021-05-08 2022-11-17 荣昌生物制药(烟台)股份有限公司 Anti-claudin 18.2 antibody and antibody-drug conjugate thereof
WO2022262859A1 (en) * 2021-06-18 2022-12-22 江苏先声药业有限公司 Anti-human msln humanized antibody and use thereof
CN116410332A (en) * 2021-12-29 2023-07-11 上海细胞治疗集团有限公司 Anti-mesothelin nano antibody chimeric antigen receptor and application thereof
WO2023157989A1 (en) * 2022-02-17 2023-08-24 주식회사 노벨티노빌리티 Antibody-drug conjugate
CN117843793A (en) * 2024-03-07 2024-04-09 深圳真实生物医药科技有限公司 Anti-mesothelin antibodies, antigen binding fragments and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1507556T1 (en) * 2002-05-02 2016-10-28 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
SG195524A1 (en) * 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
KR20120064120A (en) * 2004-06-01 2012-06-18 제넨테크, 인크. Antibody drug conjugates and methods
RS54163B1 (en) * 2006-05-30 2015-12-31 Genentech Inc. Anti-cd22 antibodies, their immunoconjugates and uses thereof
UY32560A (en) * 2009-04-29 2010-11-30 Bayer Schering Pharma Ag IMMUNOCONJUGADOS OF ANTIMESOTELINA AND USES OF THE SAME
BR112013014527A2 (en) * 2010-12-20 2017-03-07 Genentech Inc isolated antibody, isolated nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation, use of immunoconjugate, method for treating an individual who has mesothelin positive cancer, for inhibiting proliferation of a mesothelin positive cell, for detecting human mesothelin in a biological sample and for detecting mesothelin positive cancer
AU2012235817B2 (en) * 2011-04-01 2016-03-10 Wyeth Llc Antibody-drug conjugates
AR090903A1 (en) * 2012-05-01 2014-12-17 Genentech Inc ANTI-PMEL ANTIBODIES AND IMMUNOCADES17
CN106279352B (en) * 2015-05-29 2020-05-22 上海新理念生物医药科技有限公司 Derivative of dolastatin 10 and application thereof
AU2016308539B2 (en) * 2015-08-14 2019-01-24 Remegen Co., Ltd. Covalent linkers in antibody-drug conjugates and methods of making and using the same
WO2017172907A1 (en) * 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
WO2017177337A1 (en) * 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
JP6727052B2 (en) * 2016-07-19 2020-07-22 株式会社日立製作所 Biomolecule analysis device and biomolecule analysis device
CN106938051B (en) * 2016-08-22 2019-10-11 复旦大学 Target the antibody-drug conjugates of tissue factor
CA3078676A1 (en) * 2017-10-30 2019-05-09 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies

Also Published As

Publication number Publication date
SG11202006515VA (en) 2020-08-28
EP3695852A1 (en) 2020-08-19
RU2724436C1 (en) 2020-06-23
US20200138968A1 (en) 2020-05-07
AU2019272250B2 (en) 2022-01-13
KR20200098626A (en) 2020-08-20
BR112020005596A2 (en) 2020-09-29
AU2019268215B2 (en) 2021-03-18
WO2019223653A1 (en) 2019-11-28
JP2023134472A (en) 2023-09-27
AU2019272250A1 (en) 2020-03-19
CA3062265A1 (en) 2019-11-21
CN110740753A (en) 2020-01-31
CA3062265C (en) 2022-03-22
WO2019223579A1 (en) 2019-11-28
EP3797795A4 (en) 2022-04-06
US20220056147A1 (en) 2022-02-24
JP2020533398A (en) 2020-11-19
JP6949206B2 (en) 2021-10-13
KR20200120728A (en) 2020-10-21
CN110507824A (en) 2019-11-29
KR102454638B1 (en) 2022-10-14
EP3695852A4 (en) 2021-09-15
EP3797795A1 (en) 2021-03-31
TWI714092B (en) 2020-12-21
SG11202011159QA (en) 2020-12-30
CN110740754B (en) 2023-04-28
CN110740754A (en) 2020-01-31
CA3082160C (en) 2023-12-12
JP2021523874A (en) 2021-09-09
BR112020014380A2 (en) 2020-12-29
KR20230135164A (en) 2023-09-22
CA3082160A1 (en) 2019-11-28
RU2747995C1 (en) 2021-05-18
TW202003040A (en) 2020-01-16

Similar Documents

Publication Publication Date Title
AU2019268215A1 (en) Process for preparing intermediate of antibody drug conjugate
EP3250238B1 (en) Antibody drug conjugates
CN111620927B (en) One-pot preparation process of antibody drug conjugate intermediate
EP3760233A1 (en) One-pot preparation process for antibody drug conjugate intermediate
CA3085001C (en) One-pot process for preparing intermediate of antibody-drug conjugate
CN104906592B (en) Side chain connected body for pharmaceutical grade protein conjugate
JP2001500901A (en) Thioureido-cyclodextrins of particular use for dissolving antitumor and anthelmintic agents, and methods for their preparation
JPH05501865A (en) Thioacylation reagents and intermediates, thiopeptides, and methods for their preparation and use
EP3838913A1 (en) Oligopeptide linker intermediate and preparation method therefor
JP2022519002A (en) Method for preparing antibody drug conjugate intermediate by acid method and its application
CA3076714C (en) Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof
WO2022206871A1 (en) Preparation and purification method for antibody drug conjugate intermediate
EP4201429A1 (en) Antibody-drug conjugate intermediate comprising sn38 and preparation method therefor
JP4590198B2 (en) Method for producing folic acid derivative
CN114796240A (en) Self-assembled chiral short peptide medicine and preparation method and application thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)